International Affairs
Leadership Meeting
FACO International Conference
The Federation of Asian Clinical Oncology (FACO) was established in accordance of consensus of JSCO (Japan Society of Clinical Oncology), CSCO (Chinese Society of Clinical Oncology) and KSMO (Korean Society of Medical Oncology) in February 2012.
The ultimate goal of the FACO is to improve the standard of cancer treatment through the cooperate studies on more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use and also through the development of new drugs and other innovative approaches in Asian Pacific area.
The conference focus on cancer as a global challenge with the aim of improving the cure rate as well as the quality of life of cancer patients especially in Asian region.
FACO Business Meeting
22nd FACO Business Meeting at 2023 KSMO Annual Meeting in Seoul, Korea.
FACO Clinical Trial
| 1st Trial |
International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 (CONVO-GC1) PI: Kazuhiro Yoshida, Gifu University KSMO : Hyun Cheol Chung, Sun Young Rha, Han-Kwang Yang, Jae Moon Bae |
| 2nd Trial |
International Retrospective Cohort Study of Locoregional and Systemic Therapy in Oligometastatic Breast Cancer (OLIGO-BC1)
PI: Shigeru Imoto, Kyorin University KSMO : Young-Hyuck Im, Yeon Hee Park, Jeong Eon Lee, Seock-Ah Im, Sung Gwe Ahn, Kyong Hwa Park |
| 3rd Trial |
International Retrospective Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapy (PC-CURE1)
PI: Junji Furuse, Kyorin University |
| 4th Trial |
Paediatric Hepatic International Tumour Trial (PHITT)
PI: Eiso Hiyama, Hiroshima University |
|
5th Trial (2023~) |
Lung Cancer |
